Sujata Chakraborty

Company: Revolution Medicines

Job title: Senior Scientist

Seminars:

Discovery of RMC-9805, an Oral, RAS(ON)G12D-Selective Covalent Tri-Complex Inhibitor 10:00 am

The investigational agent RMC-9805 is a first-in-class, orally bioavailable, mutant selective covalent inhibitor of RASG12D(ON) that forms a tri-complex between the abundant intracellular chaperone cyclophilin A (CypA) and the “ON” state of RASG12D, enabling selective covalent engagement of Asp-12 and disrupting downstream RAS signaling by steric occlusion of effector binding RMC-9805 drove selective and persistent…Read more

day: Day Two